ArticleCancer2026
Redefining functional high-risk multiple myeloma in the context of upfront quadruplet therapy and autologous stem cell transplantation.
Article in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03224507 (Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma - MASTER Trial), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma - MASTER Trial
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFunctional high-risk (FHR) multiple myeloma (MM) was historically defined as progression within 18 months of starting therapy, with expected subsequent overall survival (OS) <2 years. The optimal definition of FHR in the era of combined quadruplet therapy (QUAD) + autologous stem cell transplantation (ASCT) is unknown.
methodsThe authors analyzed 310 patients with newly diagnosed MM who received QUAD + ASCT and had with a median follow up of 41.8 months, with 66 progression events, to identify the optimal definition of FHR MM and to explore the factors associated with outcomes of subsequent therapy.
resultsThe cumulative incidence of progression with FHR cutoff points of within 12 months (FHR12), 18 months (FHR18), 24 months (FHR24), and 36 months (FHR36) of treatment initiation were 2.6%, 6.2%, 10.1%, and 16.4%, respectively. The median second PFS (2PFS) and OS from the onset of second-line therapy were 3.0 and 8.1 months, respectively, for FHR12; 2.7 and 8.1 months, respectively, for FHR18; 3.3 and 15.7 months, respectively, for FHR24; and 5.8 and 23.8 months, respectively, for FHR36, pointing to 36 months as the optimal cutoff point to define FHR MM. The 12-month 2PFS rate was 80% versus 23% for patients treated with versus without T-cell-redirecting therapy, respectively. In multivariable analysis, T-cell-redirecting therapy was associated with a substantially improved 2PFS even when adjusted for FHR status.
conclusionsIn the current era of QUAD + ASCT, the definition of FHR MM should encompass patients who have MM with disease progression in the first 36 months of therapy. This study provides benchmark data for clinical trials deploying agents with novel mechanisms of action in this difficult-to-treat population (ClinicalTrtials.gov identifier NCT03224507).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.